571 related articles for article (PubMed ID: 25984993)
1. DNA vaccines, electroporation and their applications in cancer treatment.
Lee SH; Danishmalik SN; Sin JI
Hum Vaccin Immunother; 2015; 11(8):1889-900. PubMed ID: 25984993
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific vaccines for cancer treatment.
Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
[TBL] [Abstract][Full Text] [Related]
4. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
6. Antitumor therapeutic and antimetastatic activity of electroporation-delivered human papillomavirus 16 E7 DNA vaccines: a possible mechanism for enhanced tumor control.
Lee IH; Park JB; Cheong M; Choi YS; Park D; Sin JI
DNA Cell Biol; 2011 Dec; 30(12):975-85. PubMed ID: 21649506
[TBL] [Abstract][Full Text] [Related]
7. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.
Bråve A; Hallengärd D; Gudmundsdotter L; Stout R; Walters R; Wahren B; Hallermalm K
Vaccine; 2009 Jun; 27(28):3692-6. PubMed ID: 19428161
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation.
Roos AK; Moreno S; Leder C; Pavlenko M; King A; Pisa P
Mol Ther; 2006 Feb; 13(2):320-7. PubMed ID: 16185933
[TBL] [Abstract][Full Text] [Related]
9. NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses.
Ligtenberg MA; Rojas-Colonelli N; Kiessling R; Lladser A
Hum Vaccin Immunother; 2013 Oct; 9(10):2189-95. PubMed ID: 23884215
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses.
Ferraro B; Cisper NJ; Talbott KT; Philipson-Weiner L; Lucke CE; Khan AS; Sardesai NY; Weiner DB
Hum Vaccin; 2011; 7 Suppl():120-7. PubMed ID: 21266849
[TBL] [Abstract][Full Text] [Related]
11. Cancer vaccination by electro-gene-transfer.
Aurisicchio L; Mancini R; Ciliberto G
Expert Rev Vaccines; 2013 Oct; 12(10):1127-37. PubMed ID: 24066796
[TBL] [Abstract][Full Text] [Related]
12. A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination.
Gálvez-Cancino F; Roco J; Rojas-Colonelli N; Flores C; Murgas P; Cruz-Gómez S; Oyarce C; Varas-Godoy M; Sauma D; Lladser A
Vaccine; 2017 Jul; 35(33):4148-4154. PubMed ID: 28666759
[TBL] [Abstract][Full Text] [Related]
13. In vivo electroporation enhances vaccine-mediated therapeutic control of human papilloma virus-associated tumors by the activation of multifunctional and effector memory CD8
Sales NS; Silva JR; Aps LRMM; Silva MO; Porchia BFMM; Ferreira LCS; Diniz MO
Vaccine; 2017 Dec; 35(52):7240-7249. PubMed ID: 29174677
[TBL] [Abstract][Full Text] [Related]
14. Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor.
Lamolinara A; Stramucci L; Hysi A; Iezzi M; Marchini C; Mariotti M; Amici A; Curcio C
J Immunol Res; 2015; 2015():159145. PubMed ID: 26247038
[TBL] [Abstract][Full Text] [Related]
15. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
[TBL] [Abstract][Full Text] [Related]
16. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.
Daemi A; Bolhassani A; Rafati S; Zahedifard F; Hosseinzadeh S; Doustdari F
Immunol Lett; 2012 Dec; 148(2):117-25. PubMed ID: 23085605
[TBL] [Abstract][Full Text] [Related]
17. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model.
Ahn E; Kim H; Han KT; Sin JI
Cancer Lett; 2015 Jan; 356(2 Pt B):676-85. PubMed ID: 25449428
[TBL] [Abstract][Full Text] [Related]
18. The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA.
Ohlschläger P; Spies E; Alvarez G; Quetting M; Groettrup M
Int J Cancer; 2011 Jan; 128(2):473-81. PubMed ID: 20309939
[TBL] [Abstract][Full Text] [Related]
19. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma.
Lladser A; Ljungberg K; Tufvesson H; Tazzari M; Roos AK; Quest AF; Kiessling R
Cancer Immunol Immunother; 2010 Jan; 59(1):81-92. PubMed ID: 19526360
[TBL] [Abstract][Full Text] [Related]
20. Heparanase DNA vaccine delivered by electroporation induces humoral immunity and cytoimmunity in animal models.
Fu J; Zhao B; Dong Z; Sun Y; Luan H; Shen X; Gao X; Gong F; Li S; Song H
Vaccine; 2012 Mar; 30(12):2187-96. PubMed ID: 22240343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
